A firm with a long history, it first established an international reputation as a producer of antibiotics. Under its current CEO Isao Teshirogi, Shionogi increased its research activities in other indications during the past 10 years. This has led, for example, to the launch of the HIV drug Dolutegravir, which was developed in a joint venture with GlaxoSmithKline and Pfizer, and Xofluza, a drug for treating influenza that was licensed out to Roche.
A developer of drugs with new therapeutic approaches for its domestic market and, acting as a licensing partner, for international markets. It has also signed distribution agreements for the Japanese market, for example with Shire Pharma.